SREBF1 and cancer: Since lipogenesis is one of the key processes supporting the proliferative status of cancer cells, it is not surprising that the activity of SREBP1 is higher in cancer cells than in normal tissues and that pharmacological targeting of this transcription factor can have a favorable response in the treatment of cancer.